3-May-2024
No headlines found.
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
Business Wire (Tue, 16-Apr 7:00 AM ET)
IGC Pharma Adds Advisor in Artificial Intelligence
Business Wire (Tue, 9-Apr 9:00 AM ET)
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
Business Wire (Tue, 26-Mar 3:00 PM ET)
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation
Business Wire (Wed, 20-Mar 11:00 AM ET)
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
Business Wire (Wed, 20-Mar 7:00 AM ET)
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline
Business Wire (Tue, 12-Mar 3:00 PM ET)
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
Business Wire (Wed, 28-Feb 1:00 PM ET)
Business Wire (Fri, 23-Feb 12:01 PM ET)
IGC Pharma Reports Third Quarter Fiscal 2024 Results
Business Wire (Fri, 16-Feb 7:05 PM ET)
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Igc Pharma trades on the AMEX stock market under the symbol IGC.
As of May 3, 2024, IGC stock price declined to $0.51 with 240,676 million shares trading.
IGC has a beta of 0.39, meaning it tends to be less sensitive to market movements. IGC has a correlation of 0.00 to the broad based SPY ETF.
IGC has a market cap of $34.15 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, IGC stock traded as high as $4.65 and as low as $.25.
The top ETF exchange traded funds that IGC belongs to (by Net Assets): VXF.
IGC has outperformed the market in the last year with a price return of +54.0% while the SPY ETF gained +27.0%. IGC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +82.6% and +4.3%, respectively, while the SPY returned +3.7% and +3.3%, respectively.
IGC support price is $.46 and resistance is $.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IGC stock will trade within this expected range on the day.